The goal of this study is to evaluate a novel chemotherapy agent, GS-9219, for efficacy and toxicity in a population of dogs with a confirmed diagnosis of T cell cutaneous lymphoma. Canine cutaneous lymphoma is an uncommon but uniformly fatal canine disease. While most dogs may respond to treatment with chemotherapy, responses can be variable and are generally short in duration. New treatments for this disease are needed to improve patient comfort and survival.
Clients will be responsible for the cost of diagnosis and staging to determine eligibility prior to enrollment (~$350). You are also responsible for the cost of the recheck examination at each visit ($50), the cost of prednisone and any other ancillary medications during the study, as well as any other tests recommended by your pet’s oncologist. You are expected to make and keep all appointments, according to the clinical trial protocol once enrolled.
Dogs with biopsy confirmed cutaneous T cell lymphoma are eligible to participate. Dogs should be otherwise in good health and must have adequate organ function as determined by blood work and urinalysis. Previous treatment is allowable provided dogs have not received any chemotherapy in the past 3 weeks, radiation therapy in the past 6 weeks, or retinoid therapy in the past 7 days. West Highland White Terriers are not eligible to participate in this study because of the breed’s genetic predisposition toward idiopathic pulmonary fibrosis.
Clients participating in this study will be given special financial considerations. Specifically, all costs of blood work, urinalysis(s), x-rays and biopsies performed during the study are covered, as well all costs associated with administration of GS-9219. Additionally, a $500 credit will be applied to the pet’s account at the Foster Hospital for Small Animals at Tufts University at the completion of the study.
Kelly Reed, Oncology Liaison
Phone: (508) 887-4682